Answers are grounded in this paper and cite their sources.
Background: Brucella abortus S19 vaccination forms the cornerstone of the national brucellosis control program. Monitoring post-vaccination immune responses is crucial to assess vaccine performance across diverse regions and species. Methods: Two-phase nationwide seromonitoring study was conducted during 2021–2022 (Phase I) and 2022–2023 (Phase II) across seven geographical regions. A total of 51,759 serum samples were collected from S19-vaccinated cattle and buffalo calves of 4–8 months at four-days post-vaccination (DPV) intervals. Samples were analyzed using an in-house developed protein G-based indirect ELISA, and seroconversion rates were calculated. Statistical comparisons were performed, and spatial heterogeneity was mapped. Results: The overall seroconversion rate was 70.96%, with Phase I showing a higher seropositivity (76.05%) than Phase II (65.66%). Regionally, the Western (81.8%) and Southern (80.77%) regions showed the highest efficacy, while the Central region had the lowest (65.89%). Antibody kinetics peaked at 21–45 DPV (73.14%) and declined gradually to 43.27% by 91–120 DPV. A clear species effect was observed, with cattle calves showing higher seroconversion rates (77.12%) than buffalo calves (67.34%). Conclusions: This large-scale systematic evaluation highlights that S19 vaccine induces substantial seroconversion with regional, temporal, and species-specific differences. These insights provide crucial evidence for refining and strengthening India’s national brucellosis control program.
No takes yet. Share an insight, caveat, or question.
Shome et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: